CONNECT WITH US
HealthTech

HealthTech

Tandem wins FDA clearance for tubeless automated insulin delivery system

MedTech Dive logo

Published on

Add as a preferred source on Google
Tandem wins FDA clearance for tubeless automated insulin delivery system

The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.”

Tubed pumps deliver insulin via a tube connected to an infusion set. Tandem has turned its tubed Mobi pump into a tubeless design by replacing the infusion set with a disposable on-body kit. Users can choose to wear it as a tubed or tubeless pump.

Tandem plans to enter the tubeless pump market next year. The company committed to the launch window after receiving FDA clearance for a new infusion set and cartridge for Mobi, which is cleared for up to seven days of wear.

William Blair analysts expect “a relatively smooth transition to Mobi tubeless.” Tandem should see “little pausing of current Mobi new customer growth” because the core device remains the same, the analysts said in a note to investors. Patients interested in the new product can buy the tubed Mobi device and switch to the tubeless infusion set and cartridge when they come to market.

Patients could switch to Mobi tubeless from rival devices, Leerink analysts said. The analysts’ prediction reflects their belief that the device has “advantages in form factor and pharmacy access.” Patients who currently rely on multiple daily injections to manage their diabetes may also switch to Mobi tubeless, the analysts said.

Tandem plans a limited launch before expanding to full commercial availability in the first half of next year, William Blair analysts said. The rollout will allow the company to build manufacturing capacity and update pharmacy contracts.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.